Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SCTA01 in healthy subjects
NCT04483375Phase 1Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SCTA01 with Placebo (2 arms). Primary endpoints: Dose-limiting toxicity at 7 days and Maximal Tolerable Dose at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
upanovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04483375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483375.